Clinical trials: Paraneoplastic Syndromes
Refractory Myasthenia Gravis
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
This study is a single-center, prospective, nonrandom, single-arm trial.
- Trial name
- NCT07243366
- Testing
- CD19-CAR-NK Cells Injection
- Volunteers
- 15 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Generalized Myasthenia Gravis, Anti-AChR Antibody Positive
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
- Trial name
- NCT06967480
- Testing
- Ravulizumab
- Where
- 23 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Myasthenia Gravis
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study…
- Trial name
- NCT05332210
- Testing
- HBM9161 Injection (680mg)
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Generalized Myasthenia Gravis (gMG), Refractory gMG
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG.
- Trial name
- ECU-MG-304 (NCT06764160)
- Testing
- Eculizumab
- Where
- 6 sites in China
- Volunteers
- 15 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myasthenia Gravis
Vitaccess Real MG Registry
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL).
- Trial name
- VRMG (NCT06064461)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Vitaccess Ltd
Generalized Myasthenia Gravis
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
- Trial name
- NCT07556120
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
- Trial name
- NCT02003144
- Testing
- eculizumab
- Where
- 69 sites in United States, Argentina and 18 more
- Volunteers
- 119 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Myasthenia Gravis
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to <18 years of age (for Unites Stated (US)…
- Trial name
- NCT05265273
- Testing
- Nipocalimab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Myasthenia Gravis
The Impact of Myasthenia Gravis in the Real World
An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's…
- Trial name
- NCT04176211
- Where
- United Kingdom
- Volunteers
- 2,847 people
- Sponsor
- Vitaccess Ltd
Myasthenia Gravis, Ocular
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible…
- Trial name
- NCT07249632
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Transverse Myelitis
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects…
- Trial name
- NCT03887273
- Testing
- Q-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Q Therapeutics, Inc.
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during pregnancy.
- Trial name
- NCT06299748
- Testing
- Efgartigimod
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- argenx
Generalized Myasthenia Gravis
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT03920293
- Testing
- Ravulizumab
- Where
- 106 sites in United States, Austria and 13 more
- Volunteers
- 175 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myasthenia Gravis
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT04951622
- Testing
- Nipocalimab, Nipocalimab SC-LIV
- Where
- 112 sites in United States, Australia and 15 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Myasthenia Gravis
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the…
- Trial name
- EPIC (NCT07217587)
- Testing
- Nipocalimab, Efgartigimod
- Where
- 19 sites in United States, Israel and 1 more
- Volunteers
- 115 people
- Sponsor
- Janssen Research & Development, LLC
Generalized Myasthenia Gravis (gMG)
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
This is a Phase Ib, open-label, dose-escalation, single-center/multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of multiple doses of EA5 (a humanized…
- Trial name
- NCT07818291
- Testing
- EA5
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.
Generalized Myasthenia Gravis (gMG), gMG
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
This study aims to generate real world evidence (RWE) from Italian clinical practice on the impact of efgartigimod alfa in gMG patients encompassing clinical outcomes and patient reported experiences.
- Trial name
- POEMA (NCT07595653)
- Where
- 30 sites in Italy
- Volunteers
- 100 people
- Sponsor
- argenx